Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Time to deliver: report of the WHO Independent High-Level Commission on NCDs.

Nishtar S, Niinistö S, Sirisena M, Vázquez T, Skvortsova V, Rubinstein A, Mogae FG, Mattila P, Ghazizadeh Hashemi SH, Kariuki S, Narro Robles J, Adewole IF, Sarr AD, Gan KY, Piukala SM, Al Owais ARBM, Hargan E, Alleyne G, Alwan A, Bernaert A, Bloomberg M, Dain K, Frieden T, Patel VH, Kennedy A, Kickbusch I; Commissioners of the WHO Independent High-Level Commission on NCDs.

Lancet. 2018 Jul 21;392(10143):245-252. doi: 10.1016/S0140-6736(18)31258-3. Epub 2018 Jun 1. No abstract available.

PMID:
29866374
2.

Building laboratory capacity to support HIV care in Nigeria: Harvard/APIN PEPFAR, 2004-2012.

Hamel DJ, Sankalé JL, Samuels JO, Sarr AD, Chaplin B, Ofuche E, Meloni ST, Okonkwo P, Kanki PJ.

Afr J Lab Med. 2015;4(1). pii: 190. Epub 2015 May 14.

3.

N,N'-Dimethyl-ethylenediammonium dioxalatocuprate(II).

Gaye PA, Sarr AD, Gaye M, Sanselme M, Agasse PV.

Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67(Pt 8):m1046. doi: 10.1107/S1600536811025682. Epub 2011 Jul 9.

4.

1-(Thio-phen-2-yl)ethanone thio-semi-carbazone.

Gaye PA, Sy A, Sarr AD, Gaye M, Besnard C.

Acta Crystallogr Sect E Struct Rep Online. 2011 May 1;67(Pt 5):o1168. doi: 10.1107/S1600536811011986. Epub 2011 Apr 16.

5.

Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I, Gashau W, Meloni S, Sarr AD, Sankalé JL, Ekong E, Murphy RL, Kanki P.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):71-80. doi: 10.1089/aid.2010.0050. Epub 2010 Oct 21.

6.

4,6-Dimethyl-2-thioxo-1,2-dihydro-pyrimidin-3-ium chloride-thio-urea (1/1).

Gaye PA, Barry AH, Gaye M, Sarr AD, Sall AS.

Acta Crystallogr Sect E Struct Rep Online. 2009 May 14;65(Pt 6):o1252. doi: 10.1107/S1600536809016857.

7.

The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.

Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1285-90. doi: 10.1089/aid.2008.0072.

8.

Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.

Ulenga NK, Sarr AD, Thakore-Meloni S, Sankalé JL, Eisen G, Kanki PJ.

J Infect Dis. 2008 Aug 15;198(4):486-92. doi: 10.1086/590212.

PMID:
18598197
9.

Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

MacNeil A, Sarr AD, Sankalé JL, Meloni ST, Mboup S, Kanki P.

J Virol. 2007 May;81(10):5325-30. Epub 2007 Feb 28.

10.
11.

Long-term intrapatient viral evolution during HIV-2 infection.

MacNeil A, Sankale JL, Meloni ST, Sarr AD, Mboup S, Kanki P.

J Infect Dis. 2007 Mar 1;195(5):726-33. Epub 2007 Jan 18.

PMID:
17262716
12.

The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.

Rodriguez SK, Sarr AD, Olorunnipa O, Popper SJ, Gueye-Ndiaye A, Traoré I, Dia MC, Mboup S, Kanki PJ.

J Infect Dis. 2006 Sep 15;194(6):760-3. Epub 2006 Aug 17.

PMID:
16941341
13.

Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.

Ojesina AI, Sankalé JL, Odaibo G, Langevin S, Meloni ST, Sarr AD, Olaleye D, Kanki PJ.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):770-9.

PMID:
16910833
14.
15.

Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: differential mechanism for immunoprotection.

Hanson A, Sarr AD, Shea A, Jones N, Mboup S, Kanki P, Cao H.

AIDS Res Hum Retroviruses. 2005 Sep;21(9):791-8.

PMID:
16218803
16.

Viral dynamics of primary HIV-1 infection in Senegal, West Africa.

Sarr AD, Eisen G, Guèye-Ndiaye A, Mullins C, Traoré I, Dia MC, Sankalé JL, Faye D, Mboup S, Kanki P.

J Infect Dis. 2005 May 1;191(9):1460-7. Epub 2005 Mar 25.

PMID:
15809904
17.

Associations between MHC class I and susceptibility to HIV-2 disease progression.

Diouf K, Sarr AD, Eisen G, Popper S, Mboup S, Kanki P.

J Hum Virol. 2002 Jan-Feb;5(1):1-7.

PMID:
12352262
18.

Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals.

Dieye TN, Sow PS, Simonart T, Guèye-Ndiaye A, Popper SJ, Delforge ML, Dieye A, Sarr AD, Crusiaux A, Van Vooren JP, Devleeschouwer M, Kanki P, Mboup S, Diakhate L, Farber CM.

Vaccine. 2001 Dec 12;20(5-6):905-13.

PMID:
11738756
19.

Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay.

Sarr AD, Lu Y, Sankalé JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H.

AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1257-64.

PMID:
11559425
20.

Genetic analysis of HIV type 2 in monotypic and dual HIV infections.

Sarr AD, Sankalé JL, Guèye-Ndiaye A, Essex M, Mboup S, Kanki PJ.

AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):295-8.

PMID:
10710218
21.

Interaction with human immunodeficiency virus (HIV) type 2 predicts HIV type 1 genotype.

Sarr AD, Sankalé JL, Hamel DJ, Travers KU, Guèye-Ndiaye A, Essex M, Mboup S, Kanki PJ.

Virology. 2000 Mar 15;268(2):402-10.

22.

Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo.

Popper SJ, Sarr AD, Guèye-Ndiaye A, Mboup S, Essex ME, Kanki PJ.

J Virol. 2000 Feb;74(3):1554-7.

23.

Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

Popper SJ, Sarr AD, Travers KU, Guèye-Ndiaye A, Mboup S, Essex ME, Kanki PJ.

J Infect Dis. 1999 Oct;180(4):1116-21.

PMID:
10479138
24.

Sexually transmitted diseases and risk of HIV infection in men attending a sexually transmitted diseases clinic in Dakar, Senegal.

Thior I, Diouf G, Diaw IK, Sarr AD, Hsieh CC, Ndoye I, Mboup S, Chen L, Essex M, Marlink R, Kanki P.

Afr J Reprod Health. 1997 Sep;1(2):26-35.

PMID:
10214412
25.

Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections.

Sarr AD, Popper S, Thior I, Hamel DJ, Sankalé JL, Siby T, Marlink R, Essex M, Mboup S, Kanki P.

J Hum Virol. 1999 Jan-Feb;2(1):45-51.

PMID:
10200599
26.

HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts.

Sarr AD, Hamel DJ, Thior I, Kokkotou E, Sankalé JL, Marlink RG, Coll-Seck EM, Essex ME, Siby T, NDoye I, Mboup S, Kanki PJ.

AIDS. 1998 Jan 22;12(2):131-7.

PMID:
9468361
27.

Accuracy of two enzyme immunoassays and cell culture in the detection of Chlamydia trachomatis in low and high risk populations in Senegal.

Van Dyck E, Samb N, Sarr AD, Van de Velden L, Moran J, Mboup S, Ndoye I, Lamboray JL, Meheus A, Piot P.

Eur J Clin Microbiol Infect Dis. 1992 Jun;11(6):527-34.

PMID:
1526236

Supplemental Content

Support Center